Brava Diagnostics, Inc.

10:00 AM - 10:15 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Brava Diagnostics is developing rapid diagnostic products for the acute care market. Our first in vitro diagnostic applications are for cardiac markers, with a projected worldwide market of $2.45 billion by 2025. Our multiplex point-of-care tests will be used to assess chest pain and shortness of breath in the emergency department. The Company is seeking financing to fund development of its first product, a high-sensitivity troponin test for diagnosis of heart attack.

Brava plans to sell the Company to a large diagnostics company within 5 years and expect a valuation in excess of $500 million.

Emergency physicians need precise lab results, ideally within 15 minutes, to guide treatment or safe discharge for patients with chest pain. New guidelines are driving the shift to high-sensitivity troponin assays (hs-cTn). Central lab tests suffer from turnaround time of more than an hour. Current point-of-care tests do not meet guidelines. Brava could be among the first.
Company Type:
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
high sensitivity troponin test
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Brava Diagnostics, Inc.